Vol. 17 No. 1 (2019): Blood Transfusion - 1 2019 (January-February)
Original article
-
A model-based cost-effectiveness analysis of Patient Blood Management
-
Screening and identification of RhD antigen mimic epitopes from a phage display random peptide library for the serodiagnosis of haemolytic disease of the foetus and newborn
-
SMIM1 polymorphisms in a donor population from Southeast Brazil and their correlation with VEL expression
-
ABO blood groups and psychiatric disorders: a Croatian study
-
High resolution melting for F9 gene mutation analysis in patients with haemophilia B
Review
Letter to the Editor
-
On the cost-utility of methylene blue-photoinactivated plasma versus quarantine plasma in Spain
-
Cost of Pathogen Reduction for platelets: reply to Cicchetti et al. Blood Transfus 2018; 16: 483-9
-
Reply to "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis" by Messori et al.
-
Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis"
Announcements
Winter Closure
The Editorial Office will be closed from December 31 to January 7, 2026.
Season’s greetings to all our readers, authors, and reviewers.
Read moreSIMTI 2026
46° Convegno Nazionale di Studi di Medicina Trasfusionale - Abstract Book (in Italian)
Read moreSETS 2026
35° Congreso de la Sociedad Española de Transfusión Sanguínea y Terapia Celular - SETS - Abstract Book (in Spanish), is online (https://www.bloodtransfusion.it/bt/issue/view/81).Madrid, 4-6 June 2026.
Read moreEditorial Office Closure Notice
Please note that the BT Editorial Office will be closed until August 26, 2026.
During this period, responses to inquiries and the processing of manuscripts may be delayed. All editorial activities will resume as usual after this date.
Thank you for your understanding.
Best regards,
BT Editorial Office
Read more
Impact Factor 2025
We are pleased to announce that Blood Transfusion has achieved a 2025 Impact Factor of 2.7.
Read more